IQVIA (NYSE:IQV) Price Target Raised to $319.00

Posted by Brian Himes on Oct 2nd, 2026

IQVIA (NYSE:IQV – Free Report) had its target price increased by Royal Bank Of Canada from $247.00 to $319.00 in a report published on Tuesday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the medical research company’s stock.

IQV has been the subject of a number of other research reports. Barclays reiterated an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. JPMorgan Chase & Co. upped their price target on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. HSBC reiterated a “buy” rating and set a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research report on Thursday, July 9th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $329.00 target price (up from $300.00) on shares of IQVIA in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $264.31.

Get Our Latest Report on IQVIA

IQVIA Stock Performance

Shares of IQV opened at $260.38 on Tuesday. The company has a 50-day moving average of $254.15 and a two-hundred day moving average of $205.74. The stock has a market cap of $42.86 billion, a price-to-earnings ratio of 32.31, a PEG ratio of 2.30 and a beta of 1.17. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA has a one year low of $154.50 and a one year high of $277.40.

IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts expect that IQVIA will post 11.56 earnings per share for the current year.

Insider Buying and Selling

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,581 shares of company stock valued at $3,796,021 in the last quarter. Insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On IQVIA

A number of institutional investors and hedge funds have recently bought and sold shares of IQV. Burkett Financial Services LLC acquired a new position in IQVIA during the 3rd quarter valued at $45,000. QRG Capital Management Inc. grew its position in IQVIA by 87.7% in the 2nd quarter. QRG Capital Management Inc. now owns 58,407 shares of the medical research company’s stock worth $11,285,000 after purchasing an additional 27,283 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in shares of IQVIA by 3.7% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 4,872 shares of the medical research company’s stock valued at $941,000 after buying an additional 174 shares during the last quarter. National Pension Service lifted its stake in shares of IQVIA by 6.6% in the second quarter. National Pension Service now owns 375,973 shares of the medical research company’s stock valued at $72,646,000 after buying an additional 23,411 shares during the period. Finally, WINTON GROUP Ltd bought a new position in IQVIA during the second quarter valued at about $5,046,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.

IQVIA (NYSE:IQV) Price Target Raised to $319.00

IQVIA Stock Performance

Insider Buying and Selling

Hedge Funds Weigh In On IQVIA

IQVIA Company Profile

Further Reading

You might be interested in: